1. Pink Sheet
  2. >>Drug Safety

India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals

 
• By Anju Ghangurde

After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.

Diabetes
PATIENT DATA PERTAINING TO SGLT2 INHIBITORS ARE TO BE EXAMINED IN INDIA

In the wake of serious safety risks recently highlighted by the US FDA and Health Canada, an Indian subject expert committee (SEC), which advises the country's drug regulator on trial-related permissions and marketing clearances, has sought the examination of Indian patient data on sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

US FDA User Fee Collection Safe In Preliminary Trump 2026 Budget Plan

 
• By Cathy Kelly

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.